Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours

Data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (SSA) treatment related costs in clinical practice in the Nordic countries. Such knowledge can be of importance in a treatment decision, decision support for development of care, follow up and training of both patients and primary care nurses.

本研究所得数据将为北欧国家临床实践中的患者结局及生长抑素类似物（somatostatin analogue, SSA）治疗相关直接成本领域补充新的学术认知。此类研究成果可为治疗决策制定、照护体系发展的决策支持、患者随访工作，以及患者与基层护理护士的培训提供重要参考价值。